MedTrace Logo

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

NCT01304784 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-12-16

No results posted yet for this study

Summary

This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.

Conditions

  • HER-2 Gene Amplification

Interventions

DRUG

Cisplatin, Capecitabine, Trastuzumab and MM-111

Conventional chemotherapy

DRUG

Lapatinib +/- Trastuzumab and MM-111

Conventional chemotherapy

DRUG

Paclitaxel, Trastuzumab and MM-111

Conventional chemotherapy

DRUG

Lapatinib, trastuzumab, paclitaxel, and MM-111

Conventional chemo

DRUG

Docetaxel, trastuzumab and MM-111

Conventional chemotherapy

Sponsors & Collaborators

  • Merrimack Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Dr. Richards, MD · Tyler Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-04-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304784 on ClinicalTrials.gov